Educational objectives: 1. To understand the structural and functional features of the various anti-TNF agents, including originators and biosimilars 2. To review their use in Crohn's disease (CD), ulcerative colitis (UC) and in special indications 3. To have an overview of the optimal dosing of anti-TNFs, including therapeutic dose monitoring.
Anti-TNF were the first biological therapies available in IBD as well as in other immune-inflammatory disorders such as rheumatoid arthritis, spondyloarthritis and psoriasis. These agents can induce and maintain remission of CD and UC. They are also used in refractory pouchitis and microscopic colitis. Infliximab and adalimumab are approved in CD and UC, while certolizumab pegol is only approved for CD in some jurisdictions but not EU, and golimumab is approved for UC only. Biosimilars of infliximab and adalimumab are now available with all the indications of their originators. Data accumulate to support similar activity in both diseases, but some individual differences may be observed. Anti-TNF agents are increasingly used during pregnancy and for the treatment of extraintestinal manifestations of IBD. Infliximab remains the best studied biological agent in IBD. The possibility of iv administration at high doses makes it the favored agent in fulminant colitis, fistulizing CD and in pyoderma gangrenosum. As all biological agents, anti-TNFS can induce anti-drug antibodies that represent the main cause of loss of response to these therapies. Continuous dosing beyond induction, combination therapy and premedication with hydrocortisone reduce this risk. Therapeutic dose monitoring and antibody detection are now available for all anti-TNF agents, the proactive use of which improves treatment outcome and preserves long-term response. Based on data with infliximab, anti-TNF may decrease immune response to SARS-CoV-2 infection and may decrease vaccine response.
A discussion between a guidelines methodologist and a clinician regarding (potential) limitations of GRADE methodology and whether OCEBM still has a place in clinical guidelines.
1) A recap of strengths and challenges of using GRADE methodology
2) Discussion of the role of Oxford levels of evidence in clinical guidelines
3) Critical thought regarding how evidence based guidelines are developed
This is a tandem talk between Joana Torres and Stefanos Bonovas on clinical practice guidelines' potential benefits and harms.
Understand how to assess safety of a drug in real life practice
Understand the differences between small molecules and biologics
Understand how IBD drugs can be classified according to their safety profile
Understand how to improve IBD drug safety
Biologics differ from small molecules by many aspects, among which the chemistry, their degradation and their mechanism of action. These aspects may directly influence safety. Safety of a drug is itself difficult to quantify and qualify. The safety profile depends on the available data, strongly depending also on the time of apparition of the drug on the market and its widespread use. Most of the comparative data on safety generated through network meta-analyses or head to head trials correspond to relatively short duration of use of the drug and relatively small population compared to what would be needed to really assess safety. Therefore no or only minor differences are disclosed by these studies. If we adopt a pragmatic classification of side effects, we could classify them into mild-moderate intolerance, cumulative toxicity, major side effects that can be prevented or treated, major side effects that can hardly be prevented or treated, serious adverse events potentially lethal. When analysing the safety profiles of currently available drugs according to such classification, we find both small molecules and biologics with all these kinds of side effects. Therefore, if we can currently consider that some drugs are associated with lower or higher safety concerns, there is no difference between biologics and small molecules, the mechanism of action being sometimes closer between one small molecule and one biologic than between two biologics. Instead of safer drug or beside safer drug, we should maybe mainly aim at a safer use of these drugs.
1) To understand the limitation of current endoscopic scoring systems and why artificial intelligence may help
2) To understand the basic principles of developing artificial intelligence with its potential and limitations
3) To understand how artificial intelligence may influence patient management in the future
1/ To understand the limitation of human interpretation of endoscopic images
2/ To review the rational and goals for implementing artificial intellegence in image processing
3/ To understand the different types of artificial intelligence applications in image processing
4/ To have an overview of the future potential application of artificial intelligence in IBD endoscopy
This talk discusses the importance of sex and body image in relation to IBD and surgery. We will consider how disease and surgery affect all aspects of sex, and crucially we will examine how conversations about sex should be managed.
1. To understand how IBD can affect patients' body image and sexual pleasure
2. To consider how clinicians feel about discussing sex and address our own anxieties
3. To develop techniques and confidence in discussing sex in clinical consultations
4. To appreciate when sex should be discussed, particularly around surgery
To discuss the possibilities for achieving a 'cure' from surgical intervention in both Crohn's Disease and Ulcerative Colitis
To discuss the definition of a 'cure' in this context
To explore which patients with Crohn's disease may be at low risk of recurrence post-surgery and who may achieve a cure in the medium or long-term
To refine the role of withdrawing post-operative medical therapy in Crohn's to achieve disease- and medication-free survival
To explore emerging evidence and novel biomarkers to help stratify patients who may achieve excellent post-surgery results
To discuss the emerging potential for appendicectomy to treat/cure UC
To explore resectional and reconstructive options in UC and discuss whether these offer a 'cure' for patients
IBD cannot be cured with the currently available forms of medical therapy. However, therapeutic options can be significantly improved using an artificial intelligence-based approach that takes into consideration and integrates all omics components of the disease.
•To review the available evidence on pre-clinical studies
•To propose a common terminology for the preclinical period of disease
•To discuss important research question on the field
1. First line therapy/Monitoring
2. stratify the target
3. Anti-TNF LOR
1. To understand the role of prognostic factors in treatment decisions CD
2. To review treatment strategies in CD
3. To describe future vision of markers to guide treatment decisions
•Over the last decades we have become better in assessing treament effect by using more stringent and objective endpoints
•Nonetheless we are stuck with remission rates not over 40 %
•Head-to-head, combination trials and strategy trials are extremely important for the future
•Treat-to-target and early intervention trials have had major impact
1. To conceptualize the chronic management of complex IBD
2. To develop a multi-phased approach to combination therapy in IBD
3. To consider future strategies of management
The limitations of current treatments for IBD demand new approaches to management, including novel combinations of therapies. Combination approaches should consider multiple mechanisms, sequencing and de-escalation options. Clinical trials of novel approaches require creative and precision medicine-based strategies to demonstrate efficacy and safety as well as potential cost effectiveness.
1. To understand how risks in clinical trials are defined.
2. To review the way how the risk of clinical trials is communicated by the HCP to the patient and the shortcommings.
3. To understand the factors that influence the perception by the patient of the communicated risk.
4. To have insight in tips and tricks for an optimal communication of risk in a clinical trial setting.
1. To review current approaches to dietary therapy in adult patients with IBD
2. To discuss the use of dietary therapy to modify IBD
3. To emphasize the role of the dietitian in the multidisciplinary team